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Aim Rejection is one of the major causes of late cardiac allograft failure and at present can only be diagnosed by invasive endo-
myocardial biopsies. We sought to determine whether microRNA profiling could serve as a non-invasive biomarker of
cardiac allograft rejection.
Methods We included 113 heart transplant recipients from four referral French institutions (test cohort, n ¼ 60, validation cohort,
n ¼ 53). In the test cohort, we compared patients with acute biopsy-proven allograft rejection (n ¼ 30) to matched
control patients without rejection (n ¼ 30), by assessing microRNAs expression in the heart allograft tissue and patients
concomitant serum using RNA extraction and qPCR analysis. Fourteen miRNAs were selected on the basis of their im-
plication in allograft rejection, endothelial activation, and inflammation and tissue specificity.
Results We identified seven miRNAs that were differentially expressed between normal and rejecting heart allografts: miR-10a,
miR-21, miR-31, miR-92a, miR-142-3p miR-155, and miR-451 (P, 0.0001 for all comparisons). Four out of seven
miRNAs also showed differential serological expression (miR-10a, miR-31, miR-92a, and miR-155) with strong correl-
ation with their tissular expression. The receiver-operating characteristic analysis showed that these four circulating
miRNAs strongly discriminated patients with allograft rejection from patients without rejection: miR-10a
(AUC ¼ 0.975), miR-31 (AUC ¼ 0.932), miR-92a (AUC ¼ 0.989), and miR-155 (AUC ¼ 0.998, P, 0.0001 for all com-
parisons).Weconfirmed in the external validation set that these fourmiRNAshighlydiscriminatedpatientswith rejection
from those without. The discrimination capability of the four miRNAs remained significant when stratified by rejection
diagnosis (T-cell-mediated rejection or antibody-mediated rejection) and time post-transplant.
Conclusion This studydemonstrates that adifferential expressionofmiRNAoccurs in rejectingallograftpatients, notonlyat the tissue
level but also in the serum, suggesting their potential relevance as non-invasive biomarkers in heart transplant rejection.
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Translational perspective
Rejection still represents a major threat to heart allografts. The current gold standard for heart rejection monitoring relies on repeated heart
transplant biopsies that are invasiveproceduresand represent a seriousburden in theclinicalmanagementofheart transplant recipients.Here,
we studied in heart transplant tissue and in the concomitant serum the expression of relevant micro-RNAs involved in immune response and
relevant biology related to allograft rejection. We demonstrate that the assessment of these four miRNAs (miR-10a, miR-31, miR-92a, and
miR-155) in sera discriminates with a very high accuracy between patients with allograft rejection and those without. Taken together, our
results support that miRNAs represent relevant and non-invasive biomarkers that may serve to better investigate heart transplant rejection
and guide the clinical management of heart recipients.
Introduction
Heart transplantation is a life-saving treatment for patients with end-
stage heart failure, which represents a severe burden worldwide.1
Despite considerable advances in transplantation, allograft rejection
remains a major issue leading to allograft loss and mortality.1
Currently, the gold standard for diagnosing and monitoring acute
heart rejection relies on multiple and repeated endomyocardial biop-
sies (EMB) performed for acute clinical indications (heart failure,
decrease in left ventricular function) or carried out on a regular
basis in patients in a steady state2 in order to screen for subclinical
rejection.3,4 Despite their usefulness, EMB remains an invasive pro-
cedure associated with rare but potentially serious complications,
discomfort for the patients and increased cost for the community.
Identifying non-invasive and reliable biomarkers for screening
heart transplant rejection is one of the major challenges of solid
organ transplantation.5 While attempts have been made to isolate
such biomarkers using peripheral blood gene expression in low-risk
heart transplant recipients, this question is still unanswered.6,7
A recent breakthrough has occurred with the discovery of small
and non-coding RNAs called microRNAs that regulate gene expres-
sion.8 Though miRNAs are known to be involved in many biological
processes9 such as development,10 cell proliferation,11,12 differenti-
ation,13 apoptosis,14 and oncogenesis;15 emerging data suggest that
they may play a critical role in the regulation of immune cell develop-
ment and in the modulation of innate and adaptive immune
responses.16– 20 Consequently, miRNAs have become a potential
interest in the field of organ transplant rejection.19,20
In the present study, we hypothesized that specific miRNAs could
be used as relevant biomarkers for heart transplant rejection. We
sought to identify a miRNA signature in rejecting heart allografts
and to determine whether assessment of miRNAs post-transplant
could serve as non-invasive biomarkers of heart transplant rejection.
Such information could have a major impact on the clinical manage-
ment of heart transplant recipients.
Methods
Study design
This study included heart transplant recipients from Pompidou Hospital
(Paris, France) between January 2004 and October 2010 who had a diag-
nosis of biopsy-proven allograft rejection (n ¼ 43). Thirteen patients
were excluded because of a lack of suitable material for miRNA biopsy
assessment, leaving 30 rejecting heart allograft patients as the study
sample. This group of patients was compared with a matched control
group of 30 patients transplanted during the same period of time
but without allograft rejection. These patients were matched based
on the following criteria: recipient age, donor age, cold ischaemia
time, time from transplantation to index biopsy and maintenance
immunosuppressive regimen. All the patients had conventional graft
histopathology together with concomitant assessment of microRNA
expression in the allograft and serum taken at the time of biopsy.
We used an additional independent validation sample of 53 patients
from three heart transplant centres [Necker (n ¼ 25), Rouen (n ¼ 19),
and Pitie´-Salpe´trie`re hospitals (n ¼ 9)].
All of the transplants were ABO compatible and had current negative
IgG T cell and B cell complement-dependent cytotoxicity cross-matching
at the time of transplantation. The transplantation allocation system was
identical for all four centres and followed the rules of the French national
agency for organ procurement (Agence de la Biome´decine).
Clinical data
Clinical data for the donors and recipients in the development and valid-
ation cohorts were obtained from reviews of the patients’ charts. We
recorded the data for all the patients regarding donor age, donor
gender, recipient age, recipient gender, primary heart disease, date of
transplantation, follow-up, severe bacterial infection, CMV-related
disease, cold ischaemia time, and immunosuppressive drug regimen.
Histology and immunohistochemistry
Endomyocardial biopsies were formalin-fixed, paraffin-embedded, and
routinely stained with haematoxylin-eosin. Immunohistochemistry was
performed on tissue sections with specific antibodies: rabbit monoclonal
anti-C4d (DB Biotech, Kosice, Slovac Republic) and monoclonal
anti-CD68 (DakoCytomation, Glostrup, Denmark) using an immuno-
peroxidase method as previously described.4
Definition of heart allograft rejection
Endomyocardial biopsies were carefully examined for the presence of re-
jection by three trained pathologists (P.B., P.R., and J.P.D.V.H.) according
to updated international classification criteria. T-cell-mediated rejection
was defined according to the International Society for Heart and Lung
transplantation (ISHLT) 2004 classification.21 Antibody-mediated rejec-
tion was defined according to the last recommendation of the pathology
task force of the ISHLT22 as follows: pAMR0: no features of ABMR;
pAMR1: suspicious ABMR subdivided into pAMR1(H+) with histopath-
ology positive and immunohistochemistry negative and pAMR1(I+) with
histopathology negative and immunohistochemistry positive; pAMR2:
histopathology and immunohistochemistry both positive; pAMR3:
severe ABMR.22 The rejection episodes were considered in both test
and validation cohorts as early (occurring before 1-year post-transplant)
and late (occurring after 1-year post-transplant), Supplementary material
online, Table S1.
MicroRNA and heart transplant rejection 3195
by guest on January 23, 2015
D
ow
nloaded from
 
Detection of antibodies against donor-specific
HLA molecules
Patients with available serum at the time of biopsy were screened for the
presence of circulating anti-HLA antibodies. Antibodies against the
HLA-A, HLA-B, HLA-DR, HLA-DQ, and HLA-DP epitopes were
tested using single-antigen flow bead assays (One Lambda, Inc., Canoga
Park, CA, USA) on a Luminex platform as previously described.23,24
MicroRNA analysis
Extraction of total RNA from frozen EMBs and serum was conducted an-
onymously. Sample information was replaced by numbers, and the tech-
nician was blinded to clinical information regarding allograft rejection
status.
Extractions were performed with the Ambion Extraction Kit (Ambion,
Austin, TX, USA) and the Qiagen miRNeasy Serum/Plasma kit (Qiagen,
Venlo, The Netherlands) according to the manufacturer’s recommenda-
tions. The yield and purity of RNA were measured using a NanoDrop
ND-1000 spectrophotometer. RNAs were then individually retro-
transcribed using the microRNA reverse transcription kit (Applied Biosys-
tems). Each reverse transcription was performed with 5 mL of a 1 ng/mL
RNAsolution,7 mLofmastermix[containing100 Uof transcriptaseSuper-
script II (Invitrogen,Carlsbad,CA,USA)andamixofdNTP],3 mLof specific
miRNAs probes (Ambion, Austin, TX, USA) in a BioRad Thermal Cycler
using the following parameter values: 168C for 30 min, 428C for 30 and
858C for 5 min. MicroRNAs were then quantified by real-time PCR using
specific probes of the cDNA obtained from RT. Real-time PCR was per-
formed with 2,5 ml of RT product mixed with 15 ml of ABsoluteTM
QPCR Mix (ABgene, Epsom, UK) in a 385-well plate in a ABI 7500FAST
real-time PCR system. miRNA with more than half of the cycle threshold
(Ct) values .35 per group were excluded from the analysis.25
MicroRNA copy numbers were normalized using RNU48 small nucle-
olar RNA copy numbers to obtain DCt values. DDCt was then obtained
by subtracting the average of DCt to each DCt values. Finally, we deter-
mined fold values for each sample (2(2 DDCt)).26,27
Selection strategy of relevant miRNAs related
to allograft rejection
Selection of miRNAs was first conducted by careful in silico analysis,
studying the literature for relevant miRNAs associated with allograft
rejection. We also screened for miRNAs related to cardiovascular
pathogenesis including endothelial injury, endothelial activation, and vas-
cular inflammation.
We then performed a database screening (TargetScan.org, miRBa-
se.org, microRNA.org) to determine relevant miRNA biomarker candi-
dates according to their predicted interactions with molecules of interest
(VCAM, ICAM, eNOS, heparan sulfate, CD68, and CD40) and signalling
pathways (inflammatory, ischaemic and endothelial activation pathways,
such as mTOR or NFkappaB).
Following this analysis, we identified 14 miRNAs of interest for
heart transplant rejection (Supplementary material online, Table S2):
(i) miRNAs predominantly expressed in endothelium and associated with
endothelial activation (miR-92a, miR-126, miR-221, and miR-296);28–32
(ii) miRNAs expressed in cardiomyocytes and associated with cardio-
vascular tissue remodelling (miR-21, mi-R31, and miR-208);29,30,33,34
(iii) miRNAs related with inflammation (miR-10a, miR-142-3p, miR-155,
miR-181a, miR-181b, miR-182, and miR-451).26,35–41
In situ hybridization
MicroRNAin situ hybridization (ISH) was performed on FFPE tissue as
previously described.31 After deparaffinization of the tissue sections,
the tissue was incubated with PFA 4%, washed with PBS-DEPC and
bathed with the acetylation solution. Sections were then washed and
incubated with proteinase K (5 mg/mL) at 378C. After washing, saturation
followed with the incubation of sections with the hybridization buffer for
5 h. The probe for each miRNA (miRCURY LNA, microRNA detection
probes fromExiKon,Vedbaek,Denmark)wasthenaddedtoapreparation
containing thehybridizationbuffer,CHAPS10%andTween20%.Sections
were incubated with this solution overnight at 568C and rinsed afterward
with SSC buffers. Sections were then incubated with B1 solution and with
the blocking solution. Anti-DIG was added to the blocking solution and
sections were incubated overnight. Sections were then washed with B1
solution and a NTMT/Levamisole solution. Sections were then revealed
with NBT/BCIP mix for 3 h to 5 days depending on the specific miRNA.
Sectionswerewashed, incubated with PFA4%andmounted.Thenegative
control of ISH was performed using scrambled probe control (Supple-
mentary material online, Figure S1).
Statistical methods
Continuous variables are reportedas median, min max, and inter-quartile
range. We compared means and proportions with Student’s t-test and
thex2 test (or Fisher’s exact test if appropriate). Non-parametric analysis
(Kruskal–Wallis and Mann–Whitney tests) was performed when appro-
priate. We used a conventional receiver-operating characteristic (ROC)
curve to analyse miRNA levels to determine the cut-off points that
yielded the highest combined sensitivity and specificity with respect to
distinguishing subjects with acute rejection from subjects with normal
biopsy results. We calculated the area under the curve (AUC) and 95%
confidence intervals for the AUC. The association between intragraft
miRNAs and serum levels of miRNAs was analysed using Pearson correl-
ation coefficient.
The association of miRNAs of interest with rejection patterns was
investigated using unsupervised methods such as hierarchical cluster ana-
lysis and principal component analysis based on the combination of the
expression of the 14 miRNAs [fold values (2(2 DDCt)] obtained from
the DDCt value for each patient and each miRNA (DCt of the miRNA
for a patient – meanDCt of the population)].Hierarchical clusteranalysis
and dendrograms were performed with the hcluster module of the amap
package of the R software, while principal component analysis was
carried out using the dudi.pca module of 12 the ade4 package of the R
software (version 2.10.1). Other statistical analyses were performed
using the STATA 11.0 software (Stata Corporation, College Station,
TX, USA) and the Graphpad PRISM 5 software.
Results
Patient’s characteristics
The main analysis included 60 heart transplant patients: heart recipi-
ents with a biopsy-provenacute rejection (acute rejectiongroup,n ¼
30) and 30 matched control recipients with a normal heart allograft
biopsy (normal allograft group). The two groups were similar with
regard to recipient age, gender, primary heart disease, donor age,
cold ischaemia time and maintenance immunosuppression. The
median time since transplantation and index biopsy was also similar
between the two groups: 22 months in the rejection group
(25– 75IQR: 12–49) and 24 months (25–75IQR: 10–52). No patient
had ongoing sepsis or CMV infection at the time of index biopsy.
Anti-HLA donor-specific antibodies assessment at the time of
index EMB revealed that 2 out of 30 (7%) patients from the control
group had DSA when compared with 21/30 in the rejection group
J.- P. Duong Van Huyen et al.3196
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(70%, P, 0.0001). The baseline patient characteristics are detailed in
Table 1. The acute rejection group included 11 cases of T-cell-
mediated rejection and 19 cases of AMR. Both groups received
similar maintenance therapy. The detail of rejection histopathological
grade is given in Supplementary material online, Table S3.
MicroRNAs expression in heart allograft
biopsies
The dendrogram and unsupervised principal component analysis
were examined in all heart transplant biopsies and the respective
expression of the 14 miRNAs identified in primary analysis (Supple-
mentary material online, Figure S2). Among the 14 miRNAs, we
identified 7 miRNAs that were highly (P, 0.0001) differentially
expressed (over or under expressed) between normal and rejecting
heart allografts: miR-10a, miR-21, miR-31, miR-92a, miR-142-3p
miR-155, and miR-451 (Figure 1A). Four miRNAs (miR-126,
miR-181b, miR-182, and miR-296) showed some association with
rejection, but at a lower significance (0.001, P, 0.05). Three
remaining miRNAs were not found to be associated with rejection
(miR-181a, miR-208, and miR-221).
In situ hybridization performed in heart allograft biopsy showed
that miR-10a and MiR-92a were expressed in endothelial cells,
while MiR-31 was localized in interstitial cells (Figure 1B). In situ hy-
bridization analysis was not available for the remaining four
miRNAs of interest.
Circulating microRNAs predict cardiac
allograft rejection
We tested whether the seven miRNAs differentially expressed in
EMBs showed distinct expression in the concomitant patient’s
serum. Three miRNAs (miR-21, miR-142-3p, and miR-451) were
not amenable to qPCR amplification in the serum (CT value .35,
see Methods), leaving four miRNAs (miR-10a, miR-31, miR-92a,
and miR-155) that demonstrated distinct expression with regard to
the heart allograft status; normal vs. rejection (Figure 2). Levels of
miR-31, miR-92a, and miR-155 were significantly higher in the sera
of patients with rejecting allografts compared with patients without
rejection (P, 0.0001 for all comparisons). The level of miR-10a
was significantly lower in the sera of patients with rejecting allografts
compared with patients without rejection (P, 0.0001).
The ROC analysis showed that these four circulating miRNAs
strongly discriminated patients with allograft rejection from patients
without rejection [miR-10a: AUC ¼ 0.975, CI95% ¼ (0.946–1.005);
miR-31: AUC ¼ 0.932, CI95% ¼ (0.876–0.989), miR-92a: AUC ¼
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Baseline patient’s characteristics in the principal cohort
Normal allografts (n 5 30) Rejecting allografts (n 5 30) P-value
Recipient age, [median, IQR (25–75)] 43 (33–51) 41 (32–48) 0.6
Recipient gender, male, n (%) 21 (70) 17 (57) 0.4
Primary heart disease, n (%)
Congenital cardiopathy 4 (13) 5 (17) 1.0
Non-ischaemic cardiopathy 11 (37) 15 (50) 0.4
Ischaemic cardiopathy 10 (33) 6 (20) 0.4
Valvular cardiomyopathy 3 (10) 2 (7) 1.0
Retransplant 0 (0) 1 (3) 1.0
Miscellaneous 2 (7) 1 (3) 1.0
Donor age [median, IQR (25–75)] 44 (31–49) 42 (25–52) 0.6
Donor gender, male, n (%) 24 (80) 20 (67) 0.4
Cold ischaemia time, min [median, IQR (25–75)] 210 (147–235) 208 (120–242) 0.8
Maintenance immunosuppression n (%)
Steroids 28 (93) 29 (97) 1.0
Calcineurin inhibitors 28 (93) 30 (100) 0.5
Mycofenolate acid 25 (83) 22 (73) 0.5
m-TOR inhibitors 15 (50) 14 (47) 1.0
Azathioprine 5 (17) 2 (7) 0.4
Circulating donor specific anti-HLA antibodies
(DSA) at time of index EMB n (%)
2/30 (7) TCMR (n ¼ 2/11,18) ,0.0001*
ABMRa (n ¼ 19/19,100)
Time between Tx and Index EMB,
months IQR (25–75)
22 (12–49) 24 (10–52) 0.9
TCMR, T-cell-mediated rejection; ABMR, antibody-mediated rejection.
*P-value comparing the % of patients with circulating donor-specific anti-HLA antibodies (DSA) in the normal allograft group vs. rejecting allograft group.
aP, 0.0001: P-value comparing the % of patients with circulating donor-specific anti-HLA antibodies (DSA) in the TCMR group vs. ABMR group.
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Figure 1 (A) miRNAs differentially expressed (over- or underexpressed) between normal and rejecting heart allografts. ****P, 0.0001;
***P, 0.001; **P, 0.01; *0.01 , P, 0.05. (B) Localization of miR-92a, miR-10a and miR-31 in heart allograft by in situ hybridization. miR-92a
and miR-10a are localized in the endothelium of the microcirculation (arrows and insert). miR-31 probe stained the nuclei of interstitial cells
(arrows). U6 probe stained all nuclei (positive control).
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0.989, CI95% ¼ (0.971–1.007), and miR-155: AUC ¼ 0.998, CI95% ¼
(0.993–1.003), P, 0.0001 for all comparisons] (Figure 2).
Finally, there was a high correlation between tissue and sero-
logical expression of the four miRNAs (Pearson analysis, miR-10a:
R2 ¼ 0.369, P ¼ 0.0006; miR-31: R2 ¼ 0.207, P ¼ 0.015; miR-92a:
R2 ¼ 0.326, P ¼ 0.0015; miR-155: R2 ¼ 0.4702, P, 0.0001).
External validation of the circulating
microRNA rejection signature
The external validation set was composed of 53 heart transplant
recipients from three different centres randomly selected on the
basis of the heart allograft status: biopsy-proven acute rejection or
normal allograft biopsy, all having serum available at the time of
biopsy. The baseline characteristics of the validation set are shown
in Supplementary material online, Table S4.
Of the 53 patients included, 31 had allograft rejection (T-cell-
mediated rejection n ¼ 14 and AMR, n ¼ 17), while 22 had normal
allograft EMB (Supplementary material online, Table S3).
We confirmed that the four relevant miRNAs found in the primary
analyses highly discriminated patients with rejection from those
without (Figure 3): miR-10a [AUC ¼ 0.981, CI95% ¼ (0.947–
1.015), miR-31 (AUC ¼ 0.867, CI95% ¼ (0.771–0.963)), miR-92a
(AUC ¼ 0.959, CI95% ¼ (0.908–1.009)), and miR-155 (AUC ¼
0.974, CI95% ¼ (0.940–1.007)] (P, 0.0001 for all comparisons).
Sensitivity analysis
The sensitivity analysis was conducted to confirm that the miRNA
rejection signature was robust across the two rejection entities
(i.e. T-cell-mediated rejection and antibody-mediated rejection).
We stratified the ROC analysis by rejection diagnosis and found
that all four miRNAs were associated with T-cell-mediated rejection
[miR-10a (AUC ¼ 0.981), miR-31 (AUC ¼ 0.902), miR-92a (AUC ¼
0.977), and miR-155 (AUC ¼ 0.984, Supplementary material
online, Figure S3) and also discriminated patients with antibody-
mediated rejection (miR-10a (AUC ¼ 0.969), miR-31 (AUC ¼
0.903), miR-92a (AUC ¼ 0.984), and miR-155 (AUC ¼ 0.986),
(Supplementary material online, Figure S4 P, 0.0001 for all compar-
isons between normal and rejection biopsies]. We also confirmed
that the four miRNAs are differentially expressed in normal allografts
vs. rejecting allografts in both early (before 1 year) and late (after
1 year) rejection cases (Supplementary material online, Figure S5).
Discussion
In this study, we demonstrated that four miRNAs, miR-10a, miR-31,
miR-92a, and miR-155, showed differential tissue expression
between rejecting and normal heart allografts. We also showed
that strong correlations exist between tissue and serological expres-
sion of these four miRNAs and that their assessment in patients’ sera
permits discrimination with very high accuracy between patientswith
allograft rejection and those without. Taken together, our results
suggest that these miRNAs are of potential clinical interest as non-
invasive biomarkers of heart transplant rejection.
Personalized medicine42 has gained momentum in the transplant-
ation field.5,43 The improvement of knowledge regarding rejection
pathophysiology together with the implementation of technologies
Figure 2 Diagnostic accuracy of miRNA levels in the patient’s serum from the test cohort.
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has led to the emergence of new potential biomarker candidates for
predicting allograft rejection.19,44 In recent years, the field of kidney
transplantation has moved to molecular medicine with growing evi-
dence that molecular techniques applied to biopsies45 and urine ana-
lysis46,47 could be useful for both investigating biopsies and screening
patients at risk for allograft rejection in a non-invasive manner.
In heart transplantation, defining non-invasive and relevant bio-
markers for allograft rejection is an unmet need. This is particularly
true in the context of current clinical practice that includes repeated
and routine EMBs for screening allograft rejection, a procedure that is
not without consequences for the patient.2 An important study
published in 2006 provided proof that a peripheral blood gene-
expression profiling strategy could be used in heart transplantation
without an increased risk of serious adverse outcomes.6 However,
this study was limited by several factors including the low immuno-
logical risk of the population studied as well as the exclusive attention
to T-cell-mediated rejection without assessment of antibody-
mediated rejection,7 which today represents a serious threat to
heart allografts.3,4 Moreover, this approach was limited to the
genes expressed in leucocytes, potentially ignoring significant genes
expressed in other cell types or heart tissue specific genes. Finally,
in this study, the gene signature found in the peripheral blood was
not tested in allograft biopsies.7
MicroRNAs have recently emerged as relevant candidates in the
field of organ rejection because of their capacity to regulate thou-
sands of genes that are key elements of both innate and adaptive
immune responses.16–18 The potential interest of microRNAs lies
in the fact that their expression is regulated by several inflammatory
stimuli. Further, some miRNAs have tissue specificity and are
involved in a number of processes such the regulation of adhesion
and inflammation or angiogenesis,29,48 making them markers of
choice for microvascular inflammation observed the humoral rejec-
tion in heart transplantation.22 These properties were the basis for
selecting potentially relevant miRNAs and for testing whether
these were differentially expressed in rejecting allografts in both
tissue and peripheral blood.
The four miRNAs identified in our analysis (miR-10a, miR-155,
miR-31, and miR-92a) were specific for inflammatory burdens in
endothelial cells, inflammatory pathways, cardiomyocytes/interstitial
cells, and endothelial cells, respectively. MiR-10a has been shown to
inhibit NFkB signalling pathway and consequently is involved in in-
creasing the pro-inflammatory markers MCP-1, IL -6, IL -8, -1, and
VCAM in endothelial cells.35 Lind et al.36 described several inflamma-
tory functions of miR-155 that include its increased expression fol-
lowing the activation of the T-cell receptor, the repression of the
expression of the IFN receptor and the contribution to Ig class
switching in B cells. MiR-31 mainly regulates the expression of
E-selectin and ICAM-1 when induced by the TNF pathway49 as well
as integrins (a2, a5, and b1 subunit), indicating its major role in the
regulation of inter-/intra-cell adhesion. Finally,miR-92a targets the in-
tegrin a5, S1P1, MKK4, and eNOS, demonstrating an endothelial
tropism and a potentially important role in the vascular inflammatory
response.50 All of these functions have been linked to processes
implicated in both humoral and cellular rejection in solid organ trans-
plantation. In support of this possibility, we demonstrated that
miR-10a and MiR-92a are mainly expressed in heart allograft
Figure 3 Diagnostic accuracy of miRNA levels in the patient’s serum from the validation cohort.
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endothelial cells, which are the primary target for the alloimmune re-
sponse, while MiR-31 is localized in heart allograft interstitial cells
(note that we were not able to obtain a reliable and robust signal
for miR-155 reaching our standards for ISH).
Strengths and limitations
In this paper, we employed a unique tissue and serological approach
using relevant pathogenesis-based miRNAs that reflected immune
response and heart tissue specificity. We also used an extensive allo-
graft phenotyping with contemporary tools to diagnose cases of
T-cell and antibody-mediated rejection. Our study also includes re-
jection episodes occurring in the first year post-transplant (41%) as
well as rejection occurring after 1-year post-transplant (59%), most
of late cases antibody-mediated rejection (67% of late rejections).
Therefore, this represents stereotypical clinical situations and the
contemporary picture of allograft rejection encountered in the
modern era of heart transplantation. The important differences
that we found in miRNA expression between normal and rejecting
allografts could partly be explained by the ‘sick vs. well’ strategy as
part of our case selection criteria. While this approach is relevant
to isolate relevant biomarkers as part of discovery sets (and we con-
firmed the associations in independent validation set), our results
need to be tested in unselected prospective cohorts of heart recipi-
ents. Moreover, we used in the present study a pathogenesis-based
strategy of miRNA selection. Despite our results are robust, we
cannot exclude that other potentially relevant miRNAs could be
involved in heart allograft rejection. We believe our results will
serve as a basis for future investigations regarding the clinical rele-
vance of applying a non-invasive miRNA strategy to detect normal
or rejecting heart allografts, to establish thresholds and decisions
based on the miRNA values and to determine the kinetics of
miRNA as well as response to treatment.
Finally, we are not seeking to compare the clinical relevance of a
peripheral miRNA signature to histopathology assessment, which
still represent the gold standard for the diagnosis of heart allograft re-
jection. In current practice, a heart biopsy remains mandatory in clin-
ical situations. However, we believe that the peripheral profiling of
miRNAs could guide clinicians in the setting of stable heart allografts
and aid in monitoring and determining in which cases a screening
biopsy would be mandatory.
Conclusion
In this study, we demonstrated that regulation in the expression of
miRNAs occurs during heart transplant rejection, not only at the
tissue level but also in the patient’s serum. We also showed that
the assessment of miRNAs miR-10a, miR-31, miR-92a, and
miR-155 in patients’ sera discriminates with a very high accuracy
between patientswith allograft rejection and thosewithout. This sug-
gests that miRNAs may represent relevant and non-invasive biomar-
kers that may serve to better investigate heart transplant rejection
and guide the clinical management of heart recipients.
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Supplementary material is available at European Heart Journal online.
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